1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. InterCure Ltd.
  6. News
  7. Summary
    INCR   IL0011063760

INTERCURE LTD.

(INCR)
  Report
End-of-day quote TEL AVIV STOCK EXCHANGE  -  05-21
24.16 ILS   +1.17%
05/18Canaccord Genuity Upgrades InterCure to Buy From Speculative Buy
MT
05/17TRANSCRIPT : InterCure Ltd., Q1 2022 Earnings Call, May 17, 2022
CI
05/17InterCure Reports Q1 Revenue of $34 Million; Net Income of $6 Million; Says Revenue Growth Expected to Continue
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

InterCure : Other Report or Announcement

12/30/2021 | 11:47am EDT

INTERCURE LTD.

("Intercure")

Extraordinary General Meeting of Shareholders

of Intercure Ltd. held on December 30, 2021

REPORT OF VOTING RESULTS

Pursuant to National Instrument 51-102 Continuous Disclosure Obligations Section 11.3

HERZLIYA, ISRAEL - (December 30, 2021) Intercure Ltd. (the "Company") announces today the results of the Annual General Meeting of shareholders of the Company, held today, Thursday, December 30, 2021, in Bnei Brak, Israel (the "Meeting"). At the Meeting, all of the proposals set forth in the Company's management information circular dated November 29, 2021 (the "Circular") were approved by the required majority of the shareholders. The resolutions were as follows:

Item 1: Election of Lennie Michelson Grinbaum

Lennie Michelson Grinbaum was elected to hold office as an external director of Intercure, commencing on September 4, 2021 for a period of three years. Based on proxies received prior to the Meeting, votes were cast as follows:

FOR

Voters who voted FOR

AGAINST

WITHHELD

and are nota controlling

shareholder / have a

personal interest

Vote

14,631,775

4,805,372

327,975

1,042

% of all votes

97.80%

32.12%

2.19%

0.007%

% of all votes out of non

93.61%

6.38%

controlling shareholders /

those who have a personal

interest -

not including withheld

Item 2: Election of Gideon Hirschfeld

Gideon Hirschfeld was elected to hold office as an external director of Intercure, commencing on September 24, 2021 for a period of three years. Based on proxies received prior to the Meeting, votes were cast as follows:

FOR

Voters Who Voted FOR and

AGAINST

WITHHELD

Are Nota Controlling

Shareholder / Have a Personal

Interest

Vote

14,626,287

4,800,897

328,049

456

% of all votes

97.81%

32.10%

2.19%

0.003%

% of all votes out of non

93.6%

6.39%

controlling shareholders /

those who have a personal

interest -

not including withheld

The Circular contains a full description of the matters voted upon at the Meeting, a copy of which is available at www.sedar.com.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: http://www.intercure.co.

For further information, please contact:

Amos Cohen, Chief Financial Officer amos@canndoc-pharma.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

By Order of the Board of Directors

Date: December 30, 2021

/s/ Alexander Rabinovich

Alexander Rabinovich

Chief Executive Officer

Disclaimer

InterCure Ltd. published this content on 30 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 December 2021 16:46:06 UTC.


© Publicnow 2021
All news about INTERCURE LTD.
05/18Canaccord Genuity Upgrades InterCure to Buy From Speculative Buy
MT
05/17TRANSCRIPT : InterCure Ltd., Q1 2022 Earnings Call, May 17, 2022
CI
05/17InterCure Reports Q1 Revenue of $34 Million; Net Income of $6 Million; Says Revenue Gro..
MT
05/17InterCure Posts Higher Q1 Profit, Revenue
MT
05/16InterCure Ltd. Provides Revenue Guidance for the Second Quarter and Full Year of 2022
CI
05/16InterCure Begins 2022 with Record Breaking First Quarter Financial Results
GL
05/16InterCure Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/16InterCure to Release its Q1 2022 Results and Hold a Conference Call
GL
05/16InterCure to Release its Q1 2022 Results and Hold a Conference Call
GL
05/09InterCure to Participate in Upcoming Investor Conferences in May 2022
GL
More news
Analyst Recommendations on INTERCURE LTD.
More recommendations
Financials (USD)
Sales 2022 128 M - -
Net income 2022 17,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 324 M 324 M -
Capi. / Sales 2022 2,54x
Capi. / Sales 2023 1,83x
Nbr of Employees 350
Free-Float 62,0%
Chart INTERCURE LTD.
Duration : Period :
InterCure Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTERCURE LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
Alexander Rabinovitch Director
Amos Cohen Chief Financial Officer
Ehud Barak Chairman
Lennie Michelson Grinbaum Independent External Director
David Salton Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INTERCURE LTD.16.60%324
THERMO FISHER SCIENTIFIC-16.80%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644